The normoglycemic first-degree relatives of patients with type 2 diabetes mellitus have low circulating omentin-1 and adiponectin levels

Cytokine

Volumn 58, Issue 2, 2012, Pages 295-299

  Akbarzadeh, Samad ^a   Nabipour, Iraj ^a   Assadi, Majid ^a   Movahed, Ali ^a   Jafari, Seyed Mojtaba ^a   Motamed, Niloofar ^a   Nazem, Habibollah ^b   Haraghy, Mehrnoosh ^a   Pourbehi, Abdolreza ^b   Bargahi, Afshar ^a   Hajian, Najmeh ^a  

^a BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PAYAME NOOR UNIVERSITY   (Iran)

Author keywords

Adipocytokines; Adiponectin; Diabetes mellitus; Omentin 1; Retinol binding protein 4

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INSULIN; LIPID; PROTEIN OMENTIN 1; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHEMICAL ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELATIVE; SEX DIFFERENCE;

ADIPONECTIN; ADULT; CYTOKINES; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAMILY; FEMALE; GLUCOSE TOLERANCE TEST; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; MIDDLE AGED;

EID: 84859212044     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.02.005     Document Type: Article

References (43)

1. Gulcelik N.E., Usman A., Gurlek A. Role of adipocytokines in predicting the development of diabetes and its late complications. Endocrine 2009, 36:397-403.
2. Perseghin G., Lattuada G., De CobelliF F., et al. Serum retinol-binding protein-4, leptin, and adiponectin concentrations are related to ectopic fat accumulation. J Clin Endocrinol Metab 2007, 92:4883-4888.
3. Esteve E., Ricart W., Fernandez-Real J.M., et al. Adipocytokines and insulin resistance. the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care 2009, 32:S362-7.
4. Rabe K., Lehrke M., Parhofer K.G., et al. Adipokines and insulin resistance. Mol Med 2008, 14:741-751.
5. Kralisch S., Bluher M., Paschke M., et al. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem 2007, 7:39-45.
6. Schaffler A., Neumeier M., Herfarth H., Furst A., Scholmerich J., Buchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005, 1732:96-102.
7. Yang R.Z., Lee M.J., Hu H., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-61.
8. de Souza Batista C.M., Yang R.Z., Lee M.J., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661.
9. Tan B.K., Adya R., Farhatullah S., et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808.
10. Cho Y.M., Youn B.S., Lee H., et al. Serum retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006, 29:2457-2461.
11. Yang Q., Graham T.E., Mody N., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
12. Graham T.E., Yang Q., Bluher M., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006, 354:2552-2563.
13. Eriksson J., Franssila-Kallunki A., Ekstrand A., Saloranta C., Widen E., Schalin C., et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989, 321:337-343.
14. Stadler M., Pacini G., Petrie J., Luger A., Anderwald C. RISC Investigators. β cell (dys)function in non-diabetic offspring of diabetic patients. Diabetologia 2009, 52:2435-2444.
15. Perseghin G., Ghosh S., Gerow K., Shulman G.I. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 1997, 46:1001-1009.
16. Nabipour I., Amiri M., Imami S.R., Jahfari S.M., Shafeiae E., Nosrati A., et al. The metabolic syndrome and nonfatal ischemic heart disease; a population-based study. Int J Cardiol 2007, 118:48-53.
17. Carnevale Schianca G.P., Rossi A., Sainaghi P.P., Maduli E., Bartoli E. The significance of impaired fasting glucose versus impaired glucose tolerance. Importance of insulin secretion and resistance. Diabetes Care 2003, 26:1333-1337.
18. Moreno-Navarrete J.M., Catalan V., Ortega F., et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010, 7:27.
19. Saremi A., Asghari M., Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci 2010, 28:993-998.
20. Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011, Apr 15. [Epub ahead of print].
21. Knowles N.G., Landchild M.A., Fujimoto W.Y., Kahn S.E. Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2002, 25:292-297.
22. Warram J.H., Martin B.C., Krolewski A.S., Soeldner J.S., Kahn C.R. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990, 113:909-915.
23. Cai RC, Wei L, Di JZ, et al. Expression of omentin in adipose tissues in obese and type 2 diabetic patients. Zhonghua Yi Xue Za Zhi 2009; 89: 381-4.
24. Pan H.Y., Guo L., Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010, 88:29-33.
25. Yan P., Liu D., Long M., Ren Y., Pang J., Li R. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011, 119:257-263.
26. Cho Y.M., Youn B.S., Lee H., et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006, 29:2457-2461.
27. An C., Wang H., Liu X., et al. Serum retinol-binding protein 4 is elevated and positively associated with insulin resistance in postmenopausal women. Endocr J 2009, 56:987-996.
28. Al-Daghri N.M., Al-Attas O.S., Alokail M., et al. Retinol binding protein-4 is associated with TNF-α and not insulin resistance in subjects with type 2 diabetes mellitus and coronary heart disease. Dis Markers 2009, 26:135-140.
29. Cheng X., Zhang H. Serum retinal-binding protein 4 is positively related to insulin resistance in Chinese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009, 84:58-60.
30. Jia W., Wu H., Bao Y., et al. Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab 2007, 92:3224-3229.
31. Takebayashi K., Suetsugu M., Wakabayashi S., et al. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007, 92:2712-2719.
32. Broch M., Vendrell J., Ricart W., et al. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care 2007, 30:1802-1806.
33. Gao S., Li M., Wang Z., et al. Serum levels of retinol-binding protein-4 and its association with metabolic syndrome in first-degree relatives of type 2 diabetes mellitus. Zhonghua Yi Xue Za Zhi 2009, 89:2129-2133.
34. Lihn A.S., Ostergard T., Nyholm B., et al. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab 2003, 284:E443-8.
35. Pellme F., Smith U., Funahashi T., et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003, 52:1182-1186.
36. Civitarese A.E., Jenkinson C.P., Richardson D., et al. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes. Diabetologia 2004, 47:816-820.
37. Kowalska I., Straczkowski M., Nikowska A., et al. Plasma adiponectin concentration and tumor necrosis factor-alpha system activity in lean non-diabetic offspring of type 2 diabetic subjects. Eur J Endocrinol 2006, 154:319-324.
38. Tesauro M., Rizza S., Iantorno M., et al. Vascular, metabolic, and inflammatory abnormalities in normoglycemic offspring of patients with type 2 diabetes mellitus. Metabolism 2007, 56:413-419.
39. Sull J.W., Kim H.J., Yun J.E., et al. Serum adiponectin is associated with family history of diabetes independently of obesity and insulin resistance in healthy Korean men and women. Eur J Endocrinol 2009, 160:39-43.
40. Liu J., Wang F., Cha Y., et al. Adiponectin levels in non-obese first-degree relatives of type 2 diabetes patients and non-diabetic subjects: a 5-year follow-up study. J Int Med Res 2010, 38:792-802.
41. Hotta K., Funahashi T., Bodkin N.L., et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001, 50:1126-1133.
42. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
43. Song Y., Manson J.E., Tinker L., Howard B.V., Kuller L.H., Nathan L., et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. Diabetes Care 2007, 30:1747-1752.